On the stock market since 2020, it operates in the world of health and science. It has 355 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $991.0M in the vault; even if every debt were paid off, $510.2M would remain.
A loss of $432.8M against $0 in annual sales.
At the current pace of spending, the cash lasts about 2.3 years. After that, the company needs to find new money.
The stock trades 25% above the average analyst price target.
On our five-subject report card, CERE sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CERE is a high-risk stock — not yet profitable, and its future rides on its product catching on.